Revenue: As of FY2025 Q2, the actual value is USD 10.86 B, beating the estimate of USD 10.68 B.EPS: As of FY2025 Q2, the actual value is USD 4.28, beating the estimate of USD 3.9967.EBIT: As of FY2025 Q2, the actual value is USD 1.709 B.<h3>Life Sciences Solutions</h3><ul><li>Revenues: $2,499 million for the three months ended June 28, 2025, a 6% increase from $2,355 million in the same period in 2024.</li><li>Segment Income: $919 million for the three months ended June 28, 2025, a 6% increase from $865 million in the same period in 2024.</li><li>Segment Income Margin: 36.8% for the three months ended June 28, 2025, compared to 36.7% in the same period in 2024.</li></ul><h3>Analytical Instruments</h3><ul><li>Revenues: $1,728 million for the three months ended June 28, 2025, a 3% decrease from $1,782 million in the same period in 2024.</li><li>Segment Income: $325 million for the three months ended June 28, 2025, a 26% decrease from $439 million in the same period in 2024.</li><li>Segment Income Margin: 18.8% for the three months ended June 28, 2025, compared to 24.6% in the same period in 2024.</li></ul><h3>Specialty Diagnostics</h3><ul><li>Revenues: $1,134 million for the three months ended June 28, 2025, a 2% increase from $1,117 million in the same period in 2024.</li><li>Segment Income: $306 million for the three months ended June 28, 2025, a 3% increase from $299 million in the same period in 2024.</li><li>Segment Income Margin: 27.0% for the three months ended June 28, 2025, compared to 26.7% in the same period in 2024.</li></ul><h3>Laboratory Products and Biopharma Services</h3><ul><li>Revenues: $5,995 million for the three months ended June 28, 2025, a 4% increase from $5,758 million in the same period in 2024.</li><li>Segment Income: $825 million for the three months ended June 28, 2025, an 11% increase from $745 million in the same period in 2024.</li><li>Segment Income Margin: 13.8% for the three months ended June 28, 2025, compared to 12.9% in the same period in 2024.</li></ul><h3>Outlook</h3>Thermo Fisher Scientific Inc. expects its GAAP effective tax rate in 2025 to be between 6% and 8% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits.

Thermo Fisher Scentific | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 10.86 B